SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Smallpox fact sheet. 2001 Available at http://www.who.int/mediacentre/factsheets/smallpox/en/ Accessed: 24 September 2012.
  • 2
    World Health Organization. Poliomyelitis fact sheet. February 2012 Available at http://www.who.int/mediacentre/factsheets/fs114/en/ Accessed: 24 September 2012.
  • 3
    World Health Organization. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 209.
  • 4
    Sherlock DS. Chronic hepatitis C. Dis Mon 1994; 40: 11796.
  • 5
    Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 243641.
  • 6
    Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 88791.
  • 7
    Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012; 19: 5607.
  • 8
    Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME. The future for the treatment of genotype 4 chronic hepatitis C. Liver Int 2012; 32(Suppl. 1): 14650.
  • 9
    Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press, 2010.
  • 10
    Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18(Suppl. 1): 116.
  • 11
    Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 52938.
  • 12
    Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55(Suppl. 1): S105.
  • 13
    Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol 2006; 44: 45561.
  • 14
    Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 2718.
  • 15
    Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 2007.
  • 16
    El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53: 1507.
  • 17
    United States Department of Health & Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care & treatment of viral hepatitis. Washington, DC 2011.
  • 18
    Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090101.
  • 19
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 55867.
  • 20
    Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15: 716.
  • 21
    World Health Organization. Blood safety and availability: facts and figures from the 2007 Blood Survey. 2012 Available at http://www.drmahwish.com/publications/blood-safety-and-availability-who/ Accessed: 25 September 2012.
  • 22
    Madwar MA, El-Gindy I, Fahmy HM, Shoeb NM, Massoud BA. Hepatitis C virus transmission in family members of Egyptian patients with HCV related chronic liver disease. J Egypt Public Health Assoc 1999; 74: 31332.
  • 23
    de Waure C, Cefalo C, Chiaradia G, et al. Intrafamilial transmission of hepatitis C virus in Italy: a systematic review. J Epidemiol Community Health 2010; 64: 8438.
  • 24
    Rooney G, Gilson RJ. Sexual transmission of hepatitis C virus infection. Sex Transm Infect 1998; 74: 399404.
  • 25
    Stroffolini T, Lorenzoni U, Menniti-Ippolito F, Infantolino D, Chiaramonte M. Hepatitis C virus infection in spouses: sexual transmission or common exposure to the same risk factors? Am J Gastroenterol 2001; 96: 313841.
    Direct Link:
  • 26
    Marincovich B, Castilla J, del Romero J, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003; 79: 1602.
  • 27
    Caporaso N, Ascione A, Stroffolini T. Spread of hepatitis C virus infection within families. Investigators of an Italian Multicenter Group. J Viral Hepat 1998; 5: 6772.
  • 28
    Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Hepatis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: khuzestan. World J Gastroenterol 2006; 12: 70258.
  • 29
    Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36(5 Suppl. 1): S99105.
  • 30
    Ghosn J, Leruez-Ville M, Chaix ML. Sexual transmission of hepatitis C virus. Presse Med 2005; 34: 10348.
  • 31
    Russell M, Chen MJ, Nochajski TH, et al. Risky sexual behavior, bleeding caused by intimate partner violence, and hepatitis C virus infection in patients of a sexually transmitted disease clinic. Am J Public Health 2009; 99(Suppl. 1): S1739.
  • 32
    Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 98391.
  • 33
    Centers for Disease Control and Prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men–New York City, 2005–2010. MMWR Morb Mortal Wkly Rep 2011; 60: 94550.
  • 34
    Schmidt AJ, Rockstroh JK, Vogel M, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany–a case-control study. PLoS ONE 2011; 6: e17781.
  • 35
    Centers for Disease Control and Prevention, Division of Viral Hepatitis. Hepatitis C FAQs for health professionals. 2012 Available at http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed: 22 July 2012.
  • 36
    Mack CL, Gonzalez-Peralta RP, Gupta N, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54: 83855.
  • 37
    Centers for Disease Control and Prevention. Progress toward prevention and control of hepatitis C virus infection–Egypt, 2001-2012. MMWR Morb Mortal Wkly Rep 2012; 61: 5459.
  • 38
    Lawitz E, Poordad F, Kowdley K, et al. A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive IL28B-CC genotype infected subject. In: The International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 2012.
  • 39
    Poordad F, Lawitz E, Kowdley K, et al. 12-week interferon-free regimen of ABT-450/R+ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. In: The International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 2012.
  • 40
    Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with the all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleoside NS5B inhibitor), ± ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2) In: The International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 2012.
  • 41
    Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889900.
  • 42
    Alter HJ, Liang TJ, Hepatitis C. The end of the beginning and possibly the beginning of the end. Ann Intern Med 2012; 156: 3178.
  • 43
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 44
    Antaki N, Hermes A, Hadad M, et al. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat 2008; 15: 3836.
  • 45
    Nguyen NH, VuTien P, Garcia RT, et al. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat 2010; 17: 6917.
  • 46
    Zhou YQ, Wang XH, Hong GH, et al. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. J Viral Hepat 2011; 18: 595600.
  • 47
    Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 125062.
  • 48
    Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 52732.
  • 49
    National Institutes of Health. NIH Consensus Statement on Management of Hepatitis C. NIH Consensus State-of-the-Science Statements 2002; 19: 146.
  • 50
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 58093.
  • 51
    Gupta S, Singh R. Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response. PLoS ONE 2012; 7: e41209.
  • 52
    Hsu CS, Kao JH. Genomic variation-guided management in chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2012; 6: 497506.
  • 53
    Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 60818 e5.
  • 54
    Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100: 17729.
    Direct Link:
  • 55
    Delwaide J, El Saouda R, Gerard C, Belaiche J. Hepatitis C infection: eligibility for antiviral therapies. Eur J Gastroenterol Hepatol 2005; 17: 11859.
  • 56
    Doucette KE, Robson V, Shafran S, Kunimoto D. Improving access to care by allowing self-referral to a hepatitis C clinic. Can J Gastroenterol 2009; 23: 4214.
  • 57
    Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20: 7548.
  • 58
    Niederau C, Huppe D, Zehnter E, et al. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World J Gastroenterol 2012; 18: 133947.
  • 59
    Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 3859.
  • 60
    McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012; 32(Suppl. 1): 1516.
  • 61
    Putka B, Mullen K, Birdi S, Merheb M. The disposition of hepatitis C antibody-positive patients in an urban hospital. J Viral Hepat 2009; 16: 81421.
  • 62
    Irving WL, Smith S, Cater R, et al. Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. J Viral Hepat 2006; 13: 26471.
  • 63
    Wagner G, Ryan G, Osilla KC, et al. Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection. AIDS Patient Care STDS 2009; 23: 71525.
  • 64
    Gane E, Stedman C, Hyland R, et al. ELECTRON: Once daily PSI-7977 plus RBV in HCV GT1/2/3. In: The International Liver Congress, 47th Annual Meeting of the European Society for the Study of the Liver. Barcelona, Spain, 2012.
  • 65
    Suzuki F, Ikeda K, Toyota J, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/intolerant to peginterferon/ribavirin. In: The International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 2012.
  • 66
    Thomas DL. Advances in the treatment of hepatitis C virus infection. Top Antivir Med 2012; 20: 510.
  • 67
    Schinazi RF, Bassit L, Gavegnano C. HCV drug discovery aimed at viral eradication. J Viral Hepat 2010; 17: 7790.
  • 68
    Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156: 27990.
  • 69
    Hagan LM, Yang Z, Schinazi RF. Cost-effectiveness of all-oral, interferon-free treatment for chronic hepatitis C. In: Bridging the Sciences S2E-HCV Workshop: Seek, Test, Treat, Eradicate HCV. Atlanta, GA, 2012.
  • 70
    Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat 2012; 22: 391415.
  • 71
    Grebely J, Prins M, Hellard M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012; 12: 40814.
  • 72
    Ip PP, Nijman HW, Wilschut J, Daemen T. Therapeutic vaccination against chronic hepatitis C virus infection. Antiviral Res 2012; 96: 3650.
  • 73
    Lambotin M, Barth H, Moog C, et al. Challenges for HCV vaccine development in HIV-HCV coinfection. Expert Rev Vaccines 2012; 11: 791804.
  • 74
    World Health Organization. Initiative for vaccine research, viral cancers, hepatitis C virus. 2010 Available at http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html. Accessed: 27 September 2012.
  • 75
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 133574.
  • 76
    Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 70514.
  • 77
    Coffin PO, Stevens AM, Scott JD, Stekler JD, Golden MR. Patient acceptance of universal screening for hepatitis C virus infection. BMC Infect Dis 2011; 11: 160.
  • 78
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 15629.
  • 79
    Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 26370.
  • 80
    Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001; 111: 61421.
  • 81
    Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010; 17: 43543.
  • 82
    Morano J, Gibson B, Altice F. Correlates of HIV, HCV, and HIV/HCV co-infection in a Northeastern inner city population. In: The Liver Meeting, 63rd Annual Meeting of the America Association for the Study of Liver Diseases. Boston, MA, 2012.
  • 83
    Sutton AJ, Edmunds WJ, Gill ON. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health 2006; 6: 170.
  • 84
    Weissing L, Roy K, Sapinho D, et al. Surveillance of Hepatitis C Infection Among Injecting Drug Users in the European Union. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2006.
  • 85
    Centers for Disease Control and Prevention. IDU HIV Prevention: Hepatitis C virus and HIV coinfection. 2002 Available at http://www.cdc.gov/idu/hepatitis/hepc_and_hiv_co.pdf. Accessed: 26 September 2012.
  • 86
    Schlicting EG, Johnson ME, Brems C, et al. Validity of injecting drug users’ self report of hepatitis A, B, and C. Clin Lab Sci 2003; 16: 99106.
  • 87
    Centers for Disease Control and Prevention. Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002–2009. MMWR Morb Mortal Wkly Rep 2011; 60: 53741.
  • 88
    Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18: 43743.
  • 89
    Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 2115.
  • 90
    Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005; 40(Suppl. 5): S33945.
  • 91
    Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40(Suppl. 5): S3259.
  • 92
    Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40: 1204.
  • 93
    Martin NK, Vickerman P, Foster GR, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 113744.
  • 94
    Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000; 14: 60511.
  • 95
    Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994; 271: 11520.
  • 96
    Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34(4 Part 1): 80916.
  • 97
    Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA 2012; 307: 125960.
  • 98
    Macalino GE, Dhawan D, Rich JD. A missed opportunity: hepatitis C screening of prisoners. Am J Public Health 2005; 95: 173940.
  • 99
    Federal Bureau of Prisons. Clinical practice guidelines, evaluation and treatment of hepatitis C and cirrhosis. May 2012.
  • 100
    Federal Bureau of Prisons. Clinical practice guidelines, management of HIV. June 2011.
  • 101
    Centers for Disease Control and Prevention. Viral hepatitis populations: HIV/AIDS and viral hepatitis. 2012 Available at http://www.cdc.gov/hepatitis/Populations/hiv.htm Accessed: 26 September 12012.
  • 102
    Pramoolsinsap C, Sirikulchayanonta V, Busakorn W, et al. Coinfections with hepatitis g and/or c virus in hepatitis B-related chronic liver disease. Southeast Asian J Trop Med Public Health 1999; 30: 7419.
  • 103
    Sato S, Fujiyama S, Tanaka M, et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994; 21: 15966.
  • 104
    Brown J, Dourakis S, Karayiannis P, et al. Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease. Hepatology 1992; 15: 1759.
  • 105
    Riezu-Boj JI, Parker D, Civeira MP, et al. Detection of hepatitis C virus antibodies with new recombinant antigens: assessment in chronic liver diseases. J Hepatol 1992; 15: 30913.
  • 106
    Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 4927.
  • 107
    Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179: 12548.
  • 108
    Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 132.
  • 109
    Stoszek SK, Abdel-Hamid M, Narooz S, et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. Trans R Soc Trop Med Hyg 2006; 100: 1027.
  • 110
    Shebl FM, El-Kamary SS, Saleh DA, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol 2009; 81: 102431.
  • 111
    Valladares G, Chacaltana A, Sjogren MH. The management of HCV-infected pregnant women. Ann Hepatol 2010; 9(Suppl.): 927.
  • 112
    Sheikh SM. Hepatitis B and C: value of universal antenatal screening. J Coll Physicians Surg Pak 2009; 19: 17982.
  • 113
    Kuhn L, Aldrovandi GM, Sinkala M, et al. Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to-child HIV transmission. AIDS 2010; 24: 13747.
  • 114
    Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008; 22: 97381.
  • 115
    Fitzgerald FC, Bekker LG, Kaplan R, et al. Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa. S Afr Med J 2010; 100: 82731.
  • 116
    Madurga Revilla P, Aguar Carrascosa M, Pereda Perez A, et al. Retrospective study of risk factors of vertical transmission of hepatitis C virus. An Pediatr (Barc) 2012; 76: 33642.
  • 117
    Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral combination of Daclatasvir (NS5A inhibitor) plus Sofosbuvir (nucleotide NS5B inhibitor), with or without Ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. In: The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
  • 118
    Kowdley K, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection. In: The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
  • 119
    Everson G, Sims K, Rodriguez-Torres M, et al. An interferon-free, ribavirin-free 12-week regimen of Daclatasvir, Asunaprevir, and BMS-791325 yielded SVR4 of 94% in treatment-naive patients with genotype 1 chronic HCV infection. In: The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
  • 120
    Gane E, Pockros P, Zeuzem S, et al. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naive HCV genotype 1-infected patients. In: The International Liver Congress, 47th Annual Meeting of the European Society for the Study of the Liver, Barcelona, Spain, 2012.
  • 121
    Field J, Jacobson I, Jensen D, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir, mericitabine, and ribavirin plus or minus peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. In: The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
  • 122
    Pawlotsky J, Sarin S, Foster G, et al. Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study. In: The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
  • 123
    Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of B1201335 and B1207127, ± ribavirin, in treatment-naive patients with chronic genotype 1 HCV infection: Interim results of SOUND-C2. In: The International Liver Congress, 47th Annual Meeting of the European Society for the Study of the Liver, Barcelona, Spain, 2012.